Citations

Clear

2960 citation(s) found for "Kim, P".

Single-Molecule Detection of H2O2 Mediating Angiogenic Redox Signaling on Fluorescent Single-Walled Carbon Nanotube Array
Kim, Jong‐Ho , Patra, Chitta Ranjan , Arkalgud, Jyoti R., Boghossian, Ardemis A. , Reuel, Nigel F. , Strano, Michael S. , Zhang, Jingqing , Han, Jae‐Hee , Ahn, Jin-Ho , Mukhopadhyay, Debabrata

Mayo Clinic

ACS Nano | September 7, 2011 | Volume: 5 | Issue: 10 | Pages: 7848-7857

10.1021/nn201904t | PMID 21899329 Get It

Assessment of Renal Lesions With Blood Oxygenation Level–Dependent MRI at 3 T: Preliminary Experience
Kim, Chan Kyo , Park, Byung Kwan , Kim, EunJu, Min, Ji Hye , Kim, Bohyun

Mayo Clinic

American Journal of Roentgenology | August 23, 2011 | Volume: 197 | Issue: 3 | Pages: W489-W494

10.2214/ajr.10.6319 | PMID 21862777 Get It

Degree of Variability in Performance on Breast Cancer Quality Indicators: Findings From the Florida Initiative for Quality Cancer Care
Gray, Jhanelle E. , Laronga, Christine , Siegel, Erin M. , Lee, Ji‐Hyun , Fulp, William J. , Fletcher, Michelle , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George , Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Shibata, David , Malafa, Mokenge P. , Jacobsen, Paul B. , Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | July 15, 2011 | Volume: 7 | Issue: 4 | Pages: 247-251

10.1200/jop.2010.000174 | PMID 22043190 Get It

The Florida Initiative for Quality Cancer Care has identified how multiple aspects of breast cancer care can be improved.
MR staging accuracy for endometrial cancer based on the new FIGO stage
Shin, Kyung Eun , Park, Byung Kwan , Kim, Chan Kyo , Bae, Duk Soo, Song, Sang Yong, Kim, Bohyun, Kim, Bohyun

Mayo Clinic

Acta Radiologica | July 8, 2011 | Volume: 52 | Issue: 7 | Pages: 818-824

10.1258/ar.2011.100426 | PMID 21742787 Get It

Background Magnetic resonance imaging (MRI) has been frequently used to determine a preoperative treatment plan for gynecologic cancers. However, the MR accuracy for staging an endometrial cancer is not satisfactory based on the old FIGO staging system. Purpose To evaluate MR accuracy for staging endometrial cancer using the new FIGO staging system. Material and Methods Between January 2005 and May 2009, 199 women underwent surgery due to endometrial cancer. In each patient, an endometrial cancer was staged using MR findings based on the old FIGO staging system and then repeated according to the new FIGO staging system for comparison. Histopathologic findings were used as a standard of reference. Results The accuracy of MRI in the staging of endometrial carcinoma stage I, II, III, and IV using the old FIGO staging system were 80% (159/199), 89% (178/199), 90% (179/199), and 99% (198/199), respectively, compared to 87% (174/199), 97% (193/199), 90% (179/199), and 99% (198/199), respectively, when using the new FIGO staging criteria. The overall MR accuracy of the old and new staging systems were 51% (101/199) and 81% (161/199), respectively. Conclusion MRI has become a more useful tool in the preoperative staging of endometrial cancers using the new FIGO staging system compared to the old one with increased accuracy.
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells
Leon, Johanny Tonos De, Iwai, Aki, Féau, Clémentine, Garcia, Yenni A., Balsiger, Heather A., Storer, Cheryl L., Suro, Raquel M., Garza, Kristine M. , Kim, Yeong Sang, Chen, Yu , Ning, Yang‐Min, Fletterick, Robert J. , Guy, R. Kiplin , Trepel, Jane B. , Neckers, Leonard Μ. , Cox, Marc B. , Lee, Sunmin , Riggs, Daniel L.

Mayo Clinic

Proceedings of the National Academy of Sciences | July 5, 2011 | Volume: 108 | Issue: 29 | Pages: 11878-11883

10.1073/pnas.1105160108 | PMID 21730179 Get It

Drugs that target novel surfaces on the androgen receptor (AR) and/or novel AR regulatory mechanisms are promising alternatives for the treatment of castrate-resistant prostate cancer. The 52 kDa FK506 binding protein (FKBP52) is an important positive regulator of AR in cellular and whole animal models and represents an attractive target for the treatment of prostate cancer. We used a modified receptor-mediated reporter assay in yeast to screen a diversified natural compound library for inhibitors of FKBP52-enhanced AR function. The lead compound, termed MJC13, inhibits AR function by preventing hormone-dependent dissociation of the Hsp90-FKBP52-AR complex, which results in less hormone-bound receptor in the nucleus. Assays in early and late stage human prostate cancer cells demonstrated that MJC13 inhibits AR-dependent gene expression and androgen-stimulated prostate cancer cell proliferation.
Dietary omega-3 fatty acids and endothelium-dependent responses in porcine cerebral arteries.
Kim, P, Shimokawa, Hiroaki , Vanhoutte, P. M., Shimokawa, Hiroaki

Mayo Clinic

Stroke | June 17, 2011 | Volume: 23 | Issue: 3 | Pages: 407-413

10.1161/01.str.23.3.407 | PMID 1542904 Get It

We sought to determine the effect of dietary omega-3 polyunsaturated fatty acids on cerebrovascular endothelium-dependent responses in studies performed on isolated porcine basilar arteries. Male Yorkshire pigs (6-8 weeks old) were kept for 4 weeks on a standard diet (control group, n = 12) or on chow supplemented with polyunsaturated fatty acids (eicosapentaenoic acid, 3.5 g/day, or docosahexaenoic acid, 1.5 g/day; treated group, n = 12). Isometric tension recording of the basilar artery was carried out and responses were compared between the two groups. The regimen resulted in a decrease in the plasma arachidonic acid level and an increase in eicosapentaenoic acid. Endothelium-dependent relaxations induced by bradykinin and adenosine diphosphate were augmented in the basilar arteries of the treated group. Incubation with indomethacin (10(-5) M) prevented the augmentation of the relaxations induced by bradykinin, but not those caused by adenosine diphosphate. The indomethacin-sensitive, endothelium-dependent contractions to arachidonic acid remained comparable in the two groups, indicating that the activity of cyclooxygenase was not affected by the diet. Dietary supplementation with omega-3 polyunsaturated fatty acids enhances endothelium-dependent relaxations in the basilar artery by two mechanisms: 1) replacement of endogenous arachidonic acid and suppression of the concomitant release of vasoconstrictor prostaglandins from the endothelium, and 2) enhancement of the release of endothelium-derived relaxing factor.
Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function
Mondal, Gourish, Hwang, Eun Ju, Han, Da , Dutta, Shamit K., Karumanchi, S. Ananth , Kim, Keun Il , Sinha, Sutapa , Iyer, Seethalakshmi , Couch, Fergus J. , Mukhopadhyay, Debabrata , Karumanchi, S Ananth

Mayo Clinic

Journal of Cell Science | June 8, 2011 | Volume: 124 | Issue: 13 | Pages: 2132-2142

10.1242/jcs.087122 | PMID 21652636 Get It

One of the mechanisms of tumorigenesis is that the failure of cell division results in genetically unstable, multinucleated cells. Here we show that pVHL, a tumor suppressor protein that has been implicated in the pathogenesis of renal cell carcinoma (RCC), plays an important role in regulation of cytokinesis. We found that pVHL-deficient RCC 786-O cells were multinucleated and polyploid. Reintroduction of wild-type pVHL into these cells rescued the diploid cell population, whereas the mutant pVHL-K171G failed to do so. We demonstrate that lysine 171 of pVHL is important for the final step of cytokinesis: the midbody abscission. The pVHL-K171G caused failure to localize the ESCRT-1 interacting protein Alix and the v-SNARE complex component Endobrevin to the midbody in 786-O cells, leading to defective cytokinesis. Moreover, SUMOylation of pVHL at lysine 171 might modulate its function as a cytokinesis regulator. pVHL tumor suppressor function was also disrupted by the K171G mutation, as evidenced by the xenograft tumor formation when 786-O clones expressing pVHL-K171G were injected into mice. Most RCC cell lines show a polyploid chromosome complement and consistent heterogeneity in chromosome number. Thus, this study offers a way to explain the chromosome instability in RCC and reveals a new direction for the tumor suppressor function of pVHL, which is independent of its E3 ubiquitin ligase activity.
Response to Letter Regarding Article, “Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries”
Goyal, Abhinav , Bhatt, Deepak L. , Steg, Philippe Gabríel , Ohman, E. Magnus, Corbalán, Ramón , Eagle, Kim A., Gaxiola, Efraín, Gao, Runlin, Goto, Shinya , Smith, Sidney C. , Gersh, Bernard J. , Alberts, Mark J. , Califf, Robert M. , D’Agostino, Ralph B. , Wilson, Peter W.F. , Bhatt, Deepak L , Steg, P Gabriel

Mayo Clinic

Circulation | May 23, 2011 | Volume: 123 | Issue: 20 | Pages: No page available

10.1161/circulationaha.111.025189 Get It

Mitral and Tricuspid Annular Velocities Before and After Pericardiectomy in Patients With Constrictive Pericarditis
Veress, Gabriella, Ling, Lieng Hsi , Kim, Kye-Hun, Dal‐Bianco, Jacob P. , Schaff, Hartzell V. , Espinosa, Raúl E. , Melduni, Rowlens M. , Tajik, Jamil, Sundt, Thoralf M. , Oh, Jae K. , Schaff, Hartzell

Mayo Clinic

Circulation: Cardiovascular Imaging | May 5, 2011 | Volume: 4 | Issue: 4 | Pages: 399-407

10.1161/circimaging.110.959619 | PMID 21543641 Get It

Background— Previous studies have demonstrated that mitral annulus early diastolic (e′) velocity is increased in constrictive pericarditis (CP) and reduced in restrictive cardiomyopathy. However, those studies did not comprehensively evaluate mitral and tricuspid annular velocities before and after pericardiectomy. Methods and Results— We performed comprehensive echocardiography before and after pericardiectomy in 99 patients with CP, 52 with primary (idiopathic or postpericarditis etiology) and 47 with secondary CP (due to surgery or radiation). Overall, mean±SD mitral medial, mitral lateral, and tricuspid lateral e′ velocities were 12.2±4.2, 10.0±5.4, and 11.6±3.5 cm/s, respectively; annular late diastolic velocities were 10.3±4.3, 12.2±4.9, and 11.7±5.4 cm/s, respectively; and annular systolic (s′) velocities were 7.8±2.8, 8.2±2.1, and 11.2±3.8 cm/s, respectively. Medial e′ was equal to or greater than mitral lateral e′ in 74% of analyzable cases. With the exception of tricuspid s′, there were significant differences in all s′ and e′velocities between primary and secondary CP before pericardiectomy. After pericardiectomy, all annular velocities decreased significantly ( P <0.02 for all comparisons). The reduction in medial e′ velocity was greater than that of mitral lateral e′ velocity ( P <0.0001 and P =0.0004, respectively), and the mitral lateral/medial e′ ratio normalized ( P =0.0002). Conclusions— The mitral lateral/medial e′ ratio is reversed in three fourths of patients with CP. All annular velocities are lower in secondary compared to primary CP before pericardiectomy. After pericardiectomy, there is reduction of all annular velocities and normalization of the mitral lateral/medial e′ ratio.
Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005)
Perez, EA, Dueck, A. C. , Press, MF, Chen, B, Jenkins, RB , Kim, Choon Kwan , Wiktor, AE, Meyer, R., Villalobos, Itzel Bustos, Finnigan, Melanie, Zujewski, J., Shing, Mona, Stern, Howard M., Lingle, WL, Reinholz, MM, Slamon, DJ., Paik, Soonmyung , Ketterling, Rhett P. , Buyse, Marc

Mayo Clinic

Cancer Research | April 27, 2011 | Volume: 70 | Issue: 24_Supplement | Pages: PD10-02-PD10-02

10.1158/0008-5472.sabcs10-pd10-02 Get It

Abstract Identification of HER2 as an important cellular marker in the biology and treatment of breast cancer has highlighted the importance of reliable testing methodology. Controversy exists regarding type of test, reliability, definition of positivity, and which test may best predict for patient (pt) efficacy to anti-HER2 therapies. Purpose: To determine the concordance between HER2 results by 3 central laboratories, impact of round-robin adjudication of discordant cases, and heterogeneity in HER2 results using specimens from 3 adjuvant trials where HER2 testing was performed by local and central laboratories for enrollment. Methods: We performed a blinded round-robin exchange of randomly sampled, HER2-normal (IHC-& FISH-) and HER2-positive breast tumors among 3 central laboratories (NCCTG, BCIRG and NSABP) for confirmatory HER2 testing. The 3 laboratories performed immunohistochemistry (IHC) for HER2 using the HercepTest kit (Dako, Carpenteria, CA) and fluorescence in situ hybridization (FISH) for HER2 using the PathVysion HER2 DNA probe kit/HER2/CEN17 probe mixture (Abbott Molecular, Des Plaines, IL) on 389 tumor specimens obtained from N9831/BCIRG006 (37 IHC+/FISH+, 33 IHC+/FISH-, 36 IHC-/FISH+, 62 IHC-& FISH-) and BCIRG005 (96 IHC-& FISH-); 123 cases had ≥2 blocks examined from the same pt. HER2 positivity was defined according to FDA-approved guidelines used in the clinical trials (IHC+: 3+ complete membrane staining in &gt;10% cells; FISH+: HER2/CEN17 ratio ≥2.0). The HER2 status (IHC: 3+ vs 0-2+; FISH: amplified vs not) for each block was independently determined at each site; discordant IHC and FISH cases were adjudicated at a face-to-face meeting. Results: Independent reads were concordant across pathologists in IHC status in 351/381 (92%) cases and in FISH status in 343/373 (92%) cases. Upon adjudication, a consensus was reached on 16 and 18 of the discordant IHC and FISH cases, respectively. Among 96 BCIRG005 cases, IHC-and FISH-were confirmed in the primary block in all 96 cases. Among 59 evaluable N9831 HER2-normal cases, IHC-and FISH-were confirmed in the primary block in 57 (97%) cases (but another block tested HER2+ for 4 cases). Among 102 N9831/BCIRG006 HER2+ cases, HER2 positivity was confirmed in the primary block in 73 (72%) cases. Among 118 cases with IHC results for &gt; 1 block, the adjudicated IHC result agreed across blocks in 106 (90%) cases. Among 113 cases with FISH results for &gt;1 block, the adjudicated FISH result agreed in 107 (95%) cases. Among 53 N9831 HER2-normal cases adjudicated as IHC-& FISH-(although they all had a previous local HER2+ test), there was significant improvement in disease-free survival associated with trastuzumab given concurrently with paclitaxel after doxorubicin and cyclophosphamide compared to chemotherapy alone (HR=0.31, 95% CI 0.11-0.91; A 23 pts, 10 events; C 30 pts, 5 events). Conclusions: Excellent agreement (96%) was observed among the pathologists at adjudication, suggesting that standardized methods improve assay proficiency. HER2 heterogeneity across blocks was observed more at the protein than at the gene level. In the small subset of N9831 pts adjudicated as HER2-normal trastuzumab benefit was observed. This work was supported by NCI and Genentech. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD10-02.